12/12
12:03 pm
rmd
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/8
09:09 pm
rmd
Top 50 High-Quality Dividend Growth Stocks For December 2025 [Seeking Alpha]
Low
Report
Top 50 High-Quality Dividend Growth Stocks For December 2025 [Seeking Alpha]
12/8
09:00 am
rmd
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
Low
Report
Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy
12/7
12:34 am
rmd
Is It Too Late To Consider ResMed After Obesity and Sleep Apnea Headlines? [Yahoo! Finance]
Low
Report
Is It Too Late To Consider ResMed After Obesity and Sleep Apnea Headlines? [Yahoo! Finance]
12/3
04:33 pm
rmd
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/29
07:19 am
rmd
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD) [Yahoo! Finance]
Low
Report
Calculating The Intrinsic Value Of ResMed Inc. (NYSE:RMD) [Yahoo! Finance]
11/27
02:52 pm
rmd
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/26
07:12 am
rmd
Sleep Apnea Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts [Yahoo! Finance]
Low
Report
Sleep Apnea Devices Market Competitor Analysis Report 2025: Recent Developments, Company Strategies, Sustainability Benchmarking, Product Launches, Key Persons, and Revenue Forecasts [Yahoo! Finance]
11/21
02:05 pm
rmd
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ResMed (NYSE:RMD) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/18
06:19 am
rmd
Resmed CEO Mick Farrell on new technologies, tariffs and AI [Yahoo! Finance]
Low
Report
Resmed CEO Mick Farrell on new technologies, tariffs and AI [Yahoo! Finance]
11/16
08:18 am
rmd
Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 21% gain [Yahoo! Finance]
Low
Report
Investing in ResMed (NYSE:RMD) five years ago would have delivered you a 21% gain [Yahoo! Finance]
11/15
01:21 pm
rmd
ResMed (NYSE:RMD) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
ResMed (NYSE:RMD) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
11/10
06:21 am
rmd
22% Of This ResMed Insider's Holdings Were Sold [Yahoo! Finance]
Low
Report
22% Of This ResMed Insider's Holdings Were Sold [Yahoo! Finance]
11/3
08:03 am
rmd
ResMed (NYSE:RMD) had its price target lowered by analysts at Robert W. Baird from $320.00 to $300.00. They now have an "outperform" rating on the stock.
Low
Report
ResMed (NYSE:RMD) had its price target lowered by analysts at Robert W. Baird from $320.00 to $300.00. They now have an "outperform" rating on the stock.
10/31
11:35 am
rmd
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
Low
Report
ResMed (NYSE:RMD) had its price target raised by analysts at Royal Bank Of Canada from $300.00 to $303.00. They now have an "outperform" rating on the stock.
10/31
10:05 am
rmd
ResMed (NYSE:RMD) was given a new $305.00 price target on by analysts at Morgan Stanley.
Low
Report
ResMed (NYSE:RMD) was given a new $305.00 price target on by analysts at Morgan Stanley.
10/31
09:25 am
rmd
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
Low
Report
ResMed (NYSE:RMD) had its price target raised by analysts at KeyCorp from $298.00 to $299.00. They now have an "overweight" rating on the stock.
10/31
08:06 am
rmd
ResMed (NYSE:RMD) had its price target lowered by analysts at Mizuho from $310.00 to $300.00. They now have an "outperform" rating on the stock.
Medium
Report
ResMed (NYSE:RMD) had its price target lowered by analysts at Mizuho from $310.00 to $300.00. They now have an "outperform" rating on the stock.
10/30
10:21 pm
rmd
ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript [Seeking Alpha]
10/30
04:32 pm
rmd
ResMed (NYSE:RMD) Reports Q3 In Line With Expectations [Yahoo! Finance]
Low
Report
ResMed (NYSE:RMD) Reports Q3 In Line With Expectations [Yahoo! Finance]
10/30
04:14 pm
rmd
ResMed Non-GAAP EPS of $2.55 beats by $0.05, revenue of $1.3B misses by $30M [Seeking Alpha]
Low
Report
ResMed Non-GAAP EPS of $2.55 beats by $0.05, revenue of $1.3B misses by $30M [Seeking Alpha]
10/30
04:05 pm
rmd
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
Low
Report
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
10/21
08:04 am
rmd
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $304.00 price target on the stock, up previously from $298.00.
Low
Report
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $304.00 price target on the stock, up previously from $298.00.
10/19
04:22 am
rmd
Will PolyNovo's (ASX:PNV) New Board Addition Shape Its U.S. Medtech Strategy? [Yahoo! Finance]
Low
Report
Will PolyNovo's (ASX:PNV) New Board Addition Shape Its U.S. Medtech Strategy? [Yahoo! Finance]
10/14
07:59 am
rmd
ResMed (NYSE:RMD) was upgraded by analysts at Wells Fargo & Company to a "hold" rating.
Low
Report
ResMed (NYSE:RMD) was upgraded by analysts at Wells Fargo & Company to a "hold" rating.